Clinical Application of Incretin|Based Therapy

Glucagon-like peptide 1-based therapies for the treatment of type 2 ...

Glucagon-like peptide 1 (GLP-1) receptor agonists – GLP-1 receptor agonists are particularly appropriate for use in combination with metformin ( ...

Efficacy and Safety of Incretin Therapy in Type 2 Diabetes

In October 2006, the Food and Drug Administration approved the first oral incretin enhancer, sitagliptin, a selective DPP4 inhibitor, for use as monotherapy or ...

Comparison of efficacy between incretin-based therapies for type 2 ...

As the native GLP-1 molecule is unsuitable for routine clinical use, stimulation of GLP-1 receptors either by administration of GLP-1 agonists ...

Safety of Incretin-Based Therapies—Review of the Scientific Evidence

Abstract · Cardiovascular Effects of Incretin Hormones · Pancreatitis: Preclinical Studies · Pancreatitis: Clinical Data · Incretin Therapies and ...

Incretin-Based Therapies - Medical Clinics

25–48. In addition to the glycemic effects of GLP-1 RAs, a host of extraglycemic effects have been noted with GLP-1 RA use, and are under active study (Fig. 3).

Incretin-based therapy of metabolic disease | Ugeskriftet.dk

In addition, GLP-1, but not GIP, inhibits glucagon secretion, and together these actions form the basis for the use of GLP-1 receptor agonists ( ...

Effect of Long-term Incretin-Based Therapies on Ischemic Heart ...

Patients with type 2 diabetes mellitus (T2DM) experience many cardiovascular complications. Several studies have demonstrated the ...

Incretin therapies: highlighting common features and differences in ...

Incretin-based therapies have emerged that make use of the incretin system, which comprises the incretin hormones glucagon-like peptide-1 (GLP-1) ...

A Review of Incretin Therapies Approved and in Late-Stage ...

Incretin therapies are primarily associated with mild-to-moderate GI side effects. Clinical Relevance. Obesity is a growing global epidemic that leads to ...

Variation in responses to incretin therapy: Modifiable and non ...

Three classes of DPP-4 inhibitors (Gliptins) are in clinical use to augment the endogenous incretin effect, and these provide 80%–90% efficacy ...

Enhancing treatment success with incretin-based therapies - ACOFP

From Medical Arts Research Collaborative, Excelsior Springs, MO. KEYWORDS: Incretin;. Type 2 diabetes;. Hyperglycemia;. Patient adherence;. Hypoglycemia;.

Safety and benefit of incretin-based therapies in patients with type 2 ...

The authors have conducted a post-hoc, pooled analysis of 21 randomized, double-blind, placebo-controlled clinical trials of ≤52-week duration with the use of ...

Incretin based treatments and mortality in patients with type 2 diabetes

Conclusions Current evidence does not support the suggestion that incretin based treatment increases all cause mortality in patients with type 2 ...

Incretin mimetics and enhancers: clinical applications

The GLP-1 receptor agonists and DPP4 inhibitors are important and promising additions to diabetes therapy which will help more patients with ...

An Update on the Effect of Incretin-Based Therapies on β-Cell ...

Currently, multiple DPP4Is are approved for use in the treatment of T2DM, including sitagliptin, vildagliptin, saxagliptin, linagliptin, ...

Incretin therapies: highlighting common features and differences in ...

Over the last few years, incretin-based therapies have emerged as important agents in the treatment of type 2 diabetes (T2D).

Next Step in Incretin-Based Therapy: From Single to Dual Agonism

Clinical studies exploring the effect of GIP on food intake are limited. However, GIP appears to synergise the central satiety effect and weight ...

UpToDate: Trusted, evidence-based solutions for modern healthcare

Evidence-based clinical solutions from UpToDate are trusted by clinicians ... application of Clinical Generative AI in decision support to improve outcomes.

Breaking New Ground with Incretin Therapy in Diabetes | NEJM

The need is urgent to develop and deploy effective therapies for diabetes — especially those that reduce the risks of serious complications — across populations ...

Glucagonlike Peptide 1–Based Therapies and Risk of ...

A meta-analysis of clinical trials reported no difference for sitagliptin use compared with placebo or other oral hypoglycemics in the ...